Clinical Lymphoma, Myeloma and Leukemia, 22(7), 483-494. Cancer Media Group Clinical Lymphoma, Myeloma and Leukemia, 22(7), 483-494. CIG MEDIA GROUP, LP Clinical Lymphoma Myeloma & Leukemia r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname Schuster, M, Zijlstra, J, Casasnovas, R-O, Vermaat, J S P, Kalakonda, N, Goy, A, Choquet, S, Neste, E V D, Hill, B, Thieblemont, C, Cavallo, F, de la Cruz, F, Kuruvilla, J, Hamad, N, Jaeger, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, J-M, Follows, G, Egyed, M, Offner, F, Vassilakopoulos, T, Samal, P, Ku, M, Ma, X, Corona, K, Chamoun, K, Shah, J, Shacham, S, Kauffman, M G, Canales, M & Maerevoet, M 2022, ' Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL) : A Post-hoc Analysis of the SADAL Study ', Clinical Lymphoma, Myeloma and Leukemia, vol. 22, no. 7, pp. 483-494 . https://doi.org/10.1016/j.clml.2021.12.016 Clinical lymphoma, myeloma & leukemia, Vol. 22, no.7, p. 483-494 (2022)